^
    Back
    Association details:
    Biomarker:EGFR L833V + EGFR H835L
    Cancer:Non Small Cell Lung Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) +
    Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Zhongguo Fei Ai Za Zhi
    Title:

    A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review

    Published date:
    11/22/2023
    Excerpt:
    ...we reported a case of NSCLC patient with a rare gene compound mutation EGFR L833V/H835L, who responded to Afatinib in combination with Anilotinib treatment well after 5 months of treatment, and computed tomography (CT) showed shrinkage of lung lesions.
    DOI:
    10.3779/j.issn.1009-3419.2023.102.36